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Abstract
Aim: To investigate the therapeutic effects of fluorouracil (5-Fu) and octreotide (Oct) continuous regional arterial infusion
(CRAI,) alone or in combination, was administered in a canine model of severe acute pancreatitis (SAP).
Materials and Methods: The animals were divided into five groups; group A (Sham), group B (SAP), group C (SAP and 5-Fu),
group D (SAP and Oct), and group E (SAP and 5-Fu + Oct). Levels of amylase, a-tumor necrosis factor (TNF-a), blood urea
nitrogen (BUN), creatinine, thromboxane B2 and 6-keto- prostaglandin F1a were measured both before and after the
induction of SAP. Pathologic examination of the pancreas and kidneys was performed after termination of the study.
Results: Pathologic changes noted in the pancreas in SAP significantly improved following CRAI with either single or
combined administration of 5-Fu and Oct, where combination therapy demonstrated the lowest injury score. All treatment
groups had significantly lower levels of serum TNF-a and amylase activity (P,0.05), though only groups D and E had a lower
BUN level as compared to group B. The plasma thromboxane B2 level increased in SAP, but the ratio of thromboxane B2/6-
keto- prostaglandin F1a decreased in the treatment groups, with the combination therapy (group E) demonstrating the
lowest ratio as compared to the other 3 experimental groups (P,0.05).
Conclusions: The findings in the present study demonstrate an attenuation of SAP in a canine model following CRAI
administration with 5-Fu or Oct, alone or in combination.
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Introduction
Despite advances in intensive care, the mortality rate of severe
acute pancreatitis (SAP) still remains high, ranging from 10 up to
25% [1]. In its severe form, activation of oxygen-free radicals and
microcirculatory changes, with increased endothelial barrier
permeability, may result in a profound systemic inflammatory
response, development of remote organ injury, potentially
culminating in the multiple organ dysfunction syndrome (MODS)
[2–6].
Theinflammationandnecrosiswithinthepancreasisatriggering
factor for the development of MODS, and thus resolution of these
local events is crucial. However, compounds with a property of
suppression of the severe inflammation in pancreas are rarely
reported. By inhibiting pancreatic secretion, somatostatin and its
analogues, which have been reported to indirectly reduce MPO
activity [7], release of inflammatory mediators [8], prevention of
bacterial translocation [9] and ischemia-reperfusion injury [10],
have been used in SAP patients [11]. Also the cytotoxic drug 5-
fluorouracil (5-Fu) has been reported to alleviate the pancreatic
injurybyinhibitingtheinflammatoryresponseandauto-digestionof
the pancreas during the early stage of disease [12,13].
However, as the half-life of somatostatins is short and the
inhibitory effect on trypsin secretion is dose-dependent, the
relevance of somatostatin treatment in SAP has been questioned.
Furthermore, 5-Fu as a cytotoxic drug used for treating a non-
malignant disease still is not fully acceptable in the western world.
Continuous regional arterial infusion (CRAI) may be a useful
mode of administration in order to resolve the problems, and
CRAI has been reported as being an effective way of drug delivery
also in acute pancreatitis to obtain high drug concentrations within
the pancreas with minimal systemic toxic effects [14].
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37347The effects of CRAI with Oct or 5-Fu, alone or in combination,
has not been studied. The purpose of the present study was thus to
assess the potential therapeutic effect of CRAI with administration
of octreotide and 5-Fu in a canine model of SAP.
Materials and Methods
Animals
Nineteen adult dogs of both sexes, weighing between 10 and
13 kg, were used. The animals were supplied by the Laboratory
Animal Center of Wenzhou Medical College (Wenzhou, China),
kept under conventional conditions, and fed an ordinary
laboratory diet and water. All experiments were performed in
animals after 12 h fasting with free access to water.
Ethics Statement
The protocol for the animal experiment was approved by the
Institutional Animal Committee of Wenzhou Medical College. All
animals received care in accordance to the ‘Guide for the Care
and Use of Laboratory Animals’. Procedures using dogs were
approved by the Institutional Animal Care and Use Committee of
Wenzhou Medical College (document number: wydw2011-0001).
Experimental Protocol
The animals were randomly divided into five experimental
groups; sham group (group A; n=5) and 4 groups with SAP:
Group B (CRAI with physiological saline; n=4), group C (CRAI
with 5-Fu infusion; n=5), group D (CRAI with administration of
Oct; n=5), and group E (CRAI with 5-Fu and Oct; n=5).
Induction of Severe Acute Pancreatitis
All procedures were performed under sterile conditions. The
adult mongrel dogs were anesthetized by intravenous injection of
1.5% pentobarbital sodium (1.5 ml/kg, Beijing Chemical Reagent
Company, Beijing, China). The right femoral vein was cannulated
with a 16-gauge intravenous hyperalimentation catheter to infuse
lactated Ringer’s solution at a rate of 10 ml/kg/h. The right
femoral artery was cannulated with a 20-gauge Teflon catheter for
blood sampling. Thirty minutes before the operation, 0.5%
metronidazole injection (50 ml) and 500 mg cephalosporin were
injected in all animals to prevent infection. After an upper
abdominal midline incision, the right gastroepiploic artery was
cannulated with an epidural catheter. The tip of the catheter was
placed in the gastroduodenal artery near the pylorus, the level
confirmed by injection of methylene blue, staining the whole of the
pancreas. According to Aho et al [15], severe acute pancreatitis
was induced by the retrograde intraductal injection of 5% sodium
taurocholate (1 mL/kg; Sigma Chemical Company, St Louis,
MO, USA ) to the main pancreatic duct through a microinjection
pump at a speed of 2 mL/min. The sham group had the
cannulation procedure, though without the 5% sodium taurocho-
late injection.
Continuous Regional Arterial Infusion Therapy
Parallel with the retrograde intraductal injection of 5% sodium
taurocholate, the CRAI therapy was initiated. The CRAI
perfusate ingredients were as follows: group A (sham) and group
B (SAP) had infusion of physiological saline (2 ml/h), and in
groups C, D and E, the drugs were diluted in 50 ml physiological
saline and infused at a speed of 2 ml/h with 5-Fu (15 mg/kg;
Nantong General Pharmaceutical Factory, Nantong, Jiangsu,
China), octreotide (10 mg/kg; Novartis Pharmaceutical Co.,
Switzerland) or the combination of both drugs. The dose of both
drugs used in present study was the one corresponding to what has
been used in routine clinical practice in China.
Rehydration and electrolyte balance was kept during the
perioperative course.
Collection of Specimens
Three microliters of blood was withdrawn from the right
femoral artery at the time of abdominal incision, at the injection
of saline or 5% sodium taurocholate, and 15min, 1 h, 3 h, 6 h,
10 h after the induction of SAP. Serum was stored at 280
oC. All
dogs in the sham group were sacrificed at 36 h. Immediately
after sacrifice (by blood-letting from the abdominal aorta, the
pancreas and kidneys in the sham group were removed and
subsequently fixed with 10% formaldehyde. Corresponding
samples from the 4 experimental SAP groups were collected
from the pancreas and kidneys immediately after death from
SAP progression.
Cytokines and Biochemical Parameters
Serum amylase levels was determined by means of iodine-
amylum colorimetry and expressed in u/dl (Ningbo Cicheng
Biotechnology Reagent Factory, Ningbo, Zhejiang, China). Serum
levels of TNF-a were determined by enzyme-linked immunosor-
bent assay (ELISA; Rapidbio Company, USA) and expressed in
ng/L. Serum urea nitrogen was determined by urease-GLDH and
expressed in mmol/L (Shanghai Changzheng Biochemical
Reagent CO., LTD, Shanghai, China). Serum creatinine was
analyzed by Jaffe’s Kinetic and expressed in mmol/L and serum
TXB2, 6-k-PGF1 by radioimmunoassay and expressed in ng/L
(Suzhou Medical College, Suzhou, China). All parameters were
determined by using commercial kits and conducted according to
the protocols provided by the manufacturers.
Pathologic Analysis and Grading Criteria
Autopsy was immediately carried out after sacrifice or death
and the severity of gross lesions were scored and graded. Scoring
was based on pathologic observations as reported by Prof. Zhang
Shengdao [16]. In brief, the pancreas was cut to three sections
(head, body and tail), after which each section was divided into
four equal portions (totally 12 portions). The peripancreatic tissues
were divided into the great omentum and the mesentery between
the pancreas and duodenum (3 portions). The appearance of
haemorrhage and necrotic lesions in each portion were noted.
Totally 15 portions of tissue were harvested and observed, the
points recorded and added for evaluation. According to the total
score, the pancreas gross lesion severity was divided into four
grades: grade I: #5 points; grade II: 6–9 points; grade III: 10–13
points; grade IV: $14 points.
Pancreas and kidney specimens were harvested and fixed in
10% formaldehyde solution, embedded in paraffin, sectioned, and
stained with hematoxylin- eosin (H&E) for light microscopy. The
pathologic grading were scored as described by Schmidt et al [17],
including pancreatic edema, hemorrhage, putrescence, inflamma-
tion, as well as peripancreatic fat necrosis and calcification. The
pathologic changes in the kidneys were analyzed and classified
according to a previously described acute renal injury score [18].
The sections were examined by an experienced pathologist in a
blinded fashion.
Statistical Analysis
The data were analyzed by SPSS software (11.5 version).
Statistical significance of differences among multiple groups was
determined by one-way ANOVA (when the variance was even) or
CRAI Attenuates Severe Acute Pancreatitis
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isons were determined by SNK-q test (when the variance was
even) or Nemenyi test (when the variance was uneven). For ranked
data, statistical significance for differences was determined by Ridit
test. For all analyses, statistical significance was defined as p,0.05.
Results
Survival Time of SAP Dogs
After establishment of the SAP model, the dogs were under
anesthesia during the whole study period. All SAP dogs in groups
B and group C died within 24 h, though in groups D and group E,
two dogs survived after 24 h (Table 1). All dogs in the sham group
survived until sacrificed after 36 h post-operation.
Pathologic Examination of the Pancreas and Kidneys
At the autopsy examination, pathologic examination was
normal in group A (sham). Typical SAP features were found in
group B, including patchy putrescent with saponified spots and
color changes, and hemorrhagic ascites in the abdominal cavity.
In groups C, D and E, the changes were attenuated as compared
to group B. Among the different interventional groups, group E
(5-FU + Oct) showed significantly less changes (Figure 1).
According to the method described by Schmidt et al [17], the
scores in groups C and D were similar, both groups having
significantly lower scores as compared to group B (P,0.01). The
pathologic scores of group E were the lowest among all
experimental groups (P,0.01; Figure 1).
As comes the histological examination of the kidneys, group B
showed obvious congestion of the glomerular capillaries, swelling
of the renal tubular epithelial cells, scattered or lamellar necrosis,
protein cast, interstitial edema and inflammatory cell infiltration
[18]. In group C, the pathologic changes and score were similar to
group B. There was no significant difference in pathologic scores
between groups D and E, while both groups had lower scores than
groups B and C (P,0.05; Figure 1).
Serum Amylase Levels
There was no significant difference between parameters when
comparing the different groups before SAP was initiated. Serum
amylase levels gradually increased in all groups following
induction of SAP. In groups C and D, the amylase levels were
significantly lower than in group B at 6 and 10 hrs following SAP
induction (P,0.05). In group E, serum amylase levels significantly
decreased from 3 h and on as compared with group B (P,0.05).
In addition, serum amylase levels in group E was significantly
Table 1. Survival time in the various groups.
Group Survival time P Value
Group B vs. Group C vs. Group D vs.
Group B (n=4) 12 h 35 min 13 h 55 min 16 h 3 min 18 h 45 min
Group C (n=4) 23 h 29min 12 h 25 min 17 h 12 min 19 h 3 min 0.377
Group D (n=5) 27 h 58 min 19 h 4 min 35 h 22 h 25 min 14 h 35 min 0.020 0.119
Group E (n=5) 27 h 1 min 30 h 20 min 23 h 56 min 19 h 3 min 36 h 5 min 0.003 0.022 0.347
Group B = SAP = severe acute pancreatitis.
Group C = SAP + CRAI with 5-FU.
Group D = SAP + CRAI with octreotide.
Group E = SAP + CRAI with 5-FU and octreotide.
P value, the comparison of the statistical value between every two group.
doi:10.1371/journal.pone.0037347.t001
Figure 1. Pathological scores of the pancreas and kidneys following CRAI with 5-Fu and Octreotide (Oct). Three treatment groups have
lower pancreatic pathologic scores than SAP group. Combination using of 5-Fu and Oct significantly improved the pancreatic pathologic scores as
compared to the single use of 5-Fu or Oct. Both Oct treatment groups demonstrated lower pathologic scores than the 5-Fu group. No significant
pathologic changes were found in the sham group. *: vs. SAP group, P,0.05; q: vs. SAP group, P,0.01; $: 5-FU group vs. Oct group, P,0.05; $$: 5-FU
group vs. Oct group, P,0.01; #: 5-FU group or Oct group vs. 5-FU + Oct group, P,0.05; ##: 5-FU group or Oct group vs. 5-FU + Oct group, P,0.01.
doi:10.1371/journal.pone.0037347.g001
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6 and 10 h (P,0.05; Figure 2).
Serum TNF-a Levels
Following the establishment of SAP, serum TNF-a levels
gradually increased, reaching a peak at 1 h and then declined.
All test groups had the same pattern of TNF-a changes, but TNF-
a levels in the treated groups were significantly lower as compared
to group B at 15min and 1 h (P,0.05). No significant differences
were found among the experimental groups at the other time
points, before and after SAP-induction (P,0.05; Figure 2).
Serum Levels of Urea Nitrogen and Creatinine
Serum levels of urea nitrogen and creatinine gradually increased
within the first 10 h process in group B. No significant differences
were found between groups B and C at all time points studied. In
group D, urea nitrogen levels was significantly lower as compared
to group B at 6 and 10 h (P,0.05), but creatinine levels did not
significantly differ between groups B and C at all time points
Figure 2. CRAI with 5-Fu and Octreotide (Oct) attenuated serum parameters of pancreatitis. Three treatment groups have lower serum
levels of amylase activity, TNF-a and BUN as compared to the SAP group at different time points. The combined use of 5-Fu and Oct significantly
decreased the levels of amylase activity as compared to single use of 5-Fu or Oct. Both Oct treatment groups had a lower BUN level as compared to
the SAP group. No significant changes of serum levels of amylase activity, TNF-a, Cr and BUN were found in the sham group. *: vs. SAP group, P,0.05;
q: vs. SAP group, P,0.01; $: 5-FU group vs. Oct group, P,0.05; $$: 5-FU group vs. Oct group, P,0.01; #: 5-FU group or Oct group vs. 5-FU + Oct
group, P,0.05; ##: 5-FU group or Oct group vs. 5-FU + Oct group, P,0.01.
doi:10.1371/journal.pone.0037347.g002
CRAI Attenuates Severe Acute Pancreatitis
PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e37347studied. In group E, urea nitrogen levels was significantly lower as
compared to group B at 3, 6 and 10 h (P,0.01), but creatinine
levels did not significantly differ between groups D and E at all
time points. Serum levels of urea nitrogen in group E was
significantly lower as compared to group C at 10 h (P,0.05;
Figure 2).
Serum Levels of TXB2, 6-k-PGF1a and the Ratio of TXB2 to
6-k-PGF1a
Serum level of TXB2 significantly rose after SAP induction in all
four groups, but no significant differences were found among the
four groups at each time point. In group C, 6-k-PGF1a levels were
significantly higher as compared to group B at 6 hrs (P,0.05). In
groups D and group E, 6-k-PGF1a levels were significantly higher
as compared to group B at 6 and 10 h (P,0.05). In addition,
serum level of 6-k-PGF1a in group E was significantly higher as
compared to group C at 10 h (P,0.05; Figure 3).
In group C, the ratio of TXB2 to 6-k-PGF1a was significantly
lower as compared to group B at 6 and 10 h (P,0.05). In groups
D and E, the ratio was significantly lower as compared to group B
at 3, 6 and 10 h (P,0.05). In addition, the ratio in group D was
significantly lower as compared to group C at 10 h and the ratio in
group E was significantly higher as compared to group C at 10 h
(P,0.05; Figure 3).
Discussion
Due to the systemic release of pancreatic enzymes and
cytokines, SAP can affect remote organs. As a main initiation
factor of ARDS, the local inflammation within the pancreas plays
a crucial role in the progression of SAP. However, the effect of
CRAI with 5-Fu or/and Oct has not been known. In the present
study, a canine SAP model was developed, confirmed e.g. by
pathologic changes and an increase in serum levels of amylase
activity and TNF-a. CRAI with 5-Fu or/and Oct ameliorated the
SAP, including the otherwise occurring pathologic changes, and
increases in serum amylase and TNF-a levels. Furthermore, a
systemic protective effect provided by CRAI was noted, evidenced
by decreased levels of serum TNF-a, the ratio of TXB2 to 6-k-
PGF1a and urea nitrogen and lower scores at renal pathologic
evaluation.
Octreotide has for long been recommended in SAP treatment,
though the actual effects have been discussed [19]. Octreotide in
the treatment of SAP is dose-dependent and the effect could be
limited by the blood-pancreatic tissue interface, e.g. by impaired
microcirculation and ischemia [20–22]. CRAI has been proven to
dramatically increase the drug concentrations within the pancreas
[23,24]. In our study, CRAI with Oct in experimental SAP
significantly decreased the release of amylase into peripheral blood
and improved the effect on both the local and systemic
inflammatory response. The results confirm that the beneficial
effects of octretide are achieved locally within the pancreas. The
systemic effect should be indirect, as evidenced by a decreased
systemic inflammatory response and less endothelial injury, as
previous studies have demonstrated a decrease in endotoxin
generation, inhibition of the release of inflammatory mediators
and platelet aggregation, protection of the liver and a decrease in
ischemia-reperfusion injury [9,10,25–27]. CRAI provides a
significant increase in protease inhibitor concentrations in
pancreatic tissues, as compared to a corresponding intravenous
injection, and trypsin levels are significantly suppressed [28,29].
Though a randomized controlled trial (RCT) has not been
conducted, the benefit of CRAI has been documented [30,31].
5-Fluorouracil (5-Fu) has been tried in acute pancreatitis since
the 1970s [32,33]. Essentially, 5-Fu can decrease the synthesis of
pancreatic enzymes, or serve as a proteinase inhibitor [34,35]. In
the present study, CRAI with 5-Fu decreased the serum amylase
levels. Thus, it is thought to alleviate the pancreatic injury through
prevention of auto-digestion of the pancreas during the initial stage
of SAP [36]. Several studies in experimental pancreatitis have
shown promising results with 5-Fu treatment, such as affecting
amylase, trypsin and survival rates [32,37]. Chen et al confirmed
that 5-Fu modulated the pro-inflammatory cytokine response in
experimental acute pancreatitis [38]. Clinical studies have
documented that treatment with 5-Fu can reduce the mortality
and hospital stay [39,40]. In China, the administration of 5-Fu has
been considered as an adjuvant therapy for SAP, and been
reported associated with beneficial results [12,41].
Figure 3. CRAI with 5-Fu and Octreotide (Oct) increased the ratio of TXB2 to 6-k-PGF1a. No significant difference of TXB2 was found among
the 4 experimental groups. However, 6-k-PGF1a significantly increased in all 3 treatment groups. So the ratio of TXB2 to 6-k-PGF1a was significantly
lower in the treatment groups as compared to the SAP group. The sham group had normal TXB2, 6-k-PGF1a, and ratio of TXB2 to 6-k-PGF1a. *: vs.
SAP group, P,0.05; q: vs. SAP group, P,0.01; $: 5-FU group vs. Oct group, P,0.05; $$: 5-FU group vs. Oct group, P,0.01; #: 5-FU group or Oct
group vs. 5-FU + Oct group, P,0.05; ##: 5-FU group or Oct group vs. 5-FU + Oct group, P,0.01.
doi:10.1371/journal.pone.0037347.g003
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administered via CRAI, would achieve a synergetic effect. The
beneficial effects of the two drugs could depend upon the different
mechanisms provided by 5-Fu and octreotide, respectively. 5-Fu
mainly attenuates the local inflammation within the pancreas and
octreotide inhibits the auto-digestive effect. In this study, we found
that the CRAI with combined 5-Fu and Oct treatment showed the
best result of the studied parameters. Comparing CRAI with 5-Fu
or Oct, CRAI with 5-Fu and Oct together showed a less degree of
vacuolization, tissue edema, inflammatory cell infiltration, hem-
orrhage and necrosis within the pancreas, as well as less renal
pathologic changes and reduced urea nitrogen and creatinine. In
SAP, TNF-a effects endothelial cells, evokes the disturbances of
pancreatic microcirculation and dysfunction of remote organs.
Significant changes of peripheral concentrations of Thromboxane
A2 (TXA2) and PGI2 represent mass synthesis of both factors by
injured endothelial cells. TXA2 and PGI2 are precursor of
thromboxane B2 (TXB2) and 6-keto-prostaglandin-F1-alpha (6-k-
PGF1alpha), respectively, and participate in endothelial micro-
vascular injury. Consistent with a previous study [41], a decreased
TXB2/6-K-PGF1a (TXA2/PGI2) ratio was related to less
pathologic changes of the pancreas. Reduced endothelial injury,
reflected by a decreased TXA2/PGI2 ratio, was found following
CRAI with 5-Fu and Oct, which is a potential reason for the
improvement of SAP-associated renal injury.
The main adverse occurrence in the early phase of SAP, i.e. the
systemic inflammatory response syndrome (SIRS), the main
driving factor for the development of the acute respiratory distress
syndrome (ARDS), the dominant component of multiple organ
dysfunction syndrome (MODS) and the main cause of death [42],
might be possible to overcome by the early use of CRAI with 5-Fu
and Oct, though this of course warrants further studies in order to
verify the potential effect and clarify the mechanisms involved.
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